M Engelhardt1, R Zeiser, G Ihorst, J Finke, C I Müller. 1. Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79106 Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de
Abstract
PURPOSE: Despite the availability of combined-modality treatment for Ewing sarcoma (ES) and soft tissue sarcomas (STS), results from independent groups still indicate a poor prognosis for high-risk and metastasized patients. The benefit of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (ASCT) as compared to standard treatment is not defined. METHODS: Here, we report of HDCT in 35 consecutive adult patients with poor-risk ES or rhabdomyosarcoma (n = 11) and STS (n = 24) undergoing ASCT between July 1992 and March 2003. At a median follow-up of 100.6 months after ASCT, 11 patients are alive, with nine in sustained complete remission (CR) and each one in partial remission (PR) and stable disease. Median overall survival (OS) from ASCT was 17.1 months. Response to pretreatment, Karnofsky index > 80%, R (0) resection and first-line ASCT were associated with long-term OS (p < 0.05). CONCLUSION: These data indicate that (1) patients achieving a CR or PR following induction, with preserved performance status and R (0) resection may benefit from ASCT and (2) that this can be an useful therapeutic modality in a subset of patients, in some achieving remarkable responses.
PURPOSE: Despite the availability of combined-modality treatment for Ewing sarcoma (ES) and soft tissue sarcomas (STS), results from independent groups still indicate a poor prognosis for high-risk and metastasized patients. The benefit of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (ASCT) as compared to standard treatment is not defined. METHODS: Here, we report of HDCT in 35 consecutive adult patients with poor-risk ES or rhabdomyosarcoma (n = 11) and STS (n = 24) undergoing ASCT between July 1992 and March 2003. At a median follow-up of 100.6 months after ASCT, 11 patients are alive, with nine in sustained complete remission (CR) and each one in partial remission (PR) and stable disease. Median overall survival (OS) from ASCT was 17.1 months. Response to pretreatment, Karnofsky index > 80%, R (0) resection and first-line ASCT were associated with long-term OS (p < 0.05). CONCLUSION: These data indicate that (1) patients achieving a CR or PR following induction, with preserved performance status and R (0) resection may benefit from ASCT and (2) that this can be an useful therapeutic modality in a subset of patients, in some achieving remarkable responses.
Authors: M Engelhardt; J Douville; D Behringer; A Jähne; A Smith; R Henschler; W Lange Journal: Bone Marrow Transplant Date: 2001-02 Impact factor: 5.483
Authors: S Burdach; B van Kaick; H J Laws; S Ahrens; R Haase; D Körholz; H Pape; J Dunst; T Kahn; R Willers; B Engel; U Dirksen; C Kramm; W Nürnberger; A Heyll; R Ladenstein; H Gadner; H Jürgens; U Go el Journal: Ann Oncol Date: 2000-11 Impact factor: 32.976
Authors: R G Evans; M E Nesbit; E A Gehan; L A Garnsey; O Burgert; T J Vietti; A Cangir; M Tefft; P Thomas; F B Askin Journal: J Clin Oncol Date: 1991-07 Impact factor: 44.544
Authors: P A Meyers; M D Krailo; M Ladanyi; K W Chan; S L Sailer; P S Dickman; D L Baker; J H Davis; R B Gerbing; A Grovas; C E Herzog; K L Lindsley; W Liu-Mares; J B Nachman; L Sieger; J Wadman; R G Gorlick Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: Brent A Williams; Kelly M Williams; John Doyle; Derek Stephens; Mark Greenberg; David Malkin; Alberto S Pappo Journal: J Pediatr Hematol Oncol Date: 2004-04 Impact factor: 1.289
Authors: M E Horowitz; T J Kinsella; L H Wexler; J Belasco; T Triche; M Tsokos; S M Steinberg; L McClure; D L Longo; R G Steis Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544
Authors: Dagmar Adamkova Krakorova; Katerina Kubackova; Ladislav Dusek; Tomas Tomas; Pavel Janicek; Stepan Tucek; Jana Prausova; Igor Kiss; Iva Zambo Journal: Pathol Oncol Res Date: 2017-08-12 Impact factor: 3.201
Authors: Frank Peinemann; Nicolaus Kröger; Carmen Bartel; Ulrich Grouven; Max Pittler; Rudolf Erttmann; Michael Kulig Journal: PLoS One Date: 2011-02-23 Impact factor: 3.240
Authors: Wolfgang Lamm; Werner Rabitsch; Wolfgang J Köstler; Peter Kalhs; Philipp Ubl; Thomas Brodowicz Journal: Wien Klin Wochenschr Date: 2013-02-26 Impact factor: 1.704
Authors: Lianne M Haveman; Roelof van Ewijk; Elvira C van Dalen; Willemijn B Breunis; Leontien Cm Kremer; Henk van den Berg; Uta Dirksen; Johannes Hm Merks Journal: Cochrane Database Syst Rev Date: 2021-09-02
Authors: Michela Maur; Angela Toss; Massimo Dominici; Antonio Frassoldati; Paolo Corradini; Antonio Maiorana; Annalisa Fontana; Pierfranco Conte Journal: Am J Case Rep Date: 2015-07-03
Authors: Dagmar Adamkova Krakorova; Jana Halamkova; Stepan Tucek; Ondrej Bilek; Jan Kristek; Tomas Kazda; Iva Staniczkova Zambo; Regina Demlova; Igor Kiss Journal: Medicine (Baltimore) Date: 2021-03-19 Impact factor: 1.817